Cannabis News

Industry-backed cannabis group calls foul on AMA recommendations

Published

6 months ago

October 17, 2025

admin

The Cannabis Council of Australia represents organizations such as Montu, whose portfolio includes the Alternaleaf telehealth clinic, Leafio distribution, uMeds fulfillment and Saged clinical education, to name but a few Montu branded cannabis products.

Non-executive board members include pharmaceutical product wholesalers, pharmacies, drugstores and distributors.

In direct response to a letter sent to Health Minister Mark Butler earlier this week by the AMA and the confederation calling for action on the medicinal cannabis industry, the CCA has released a statement of its own.

“The Council and the AMA have identified gaps in oversight, but a ban is not the answer,” said CCA CEO Lisa Penlington.

Ms. Penlington took particular issue with the AMA and the guild’s call for an immediate ban on products with THC concentrations above 98%.

Cannabis News

Cresco Labs gets Texas license

Published

12 hours ago

April 4, 2026

admin

Cresco Labs has obtained a Texas Compassionate Use Program License. It is a vertically integrated license that allows Cresco Labs to cultivate, process and distribute medical cannabis.

“Texas patients deserve access to consistent, quality medicine, and we’re excited. Our track record in medical markets reflects our ability to build strong programs that put patients and communities first,” said Charlie Bachtell, CEO of Cresco Labs. “Winning a license in Texas through a merit-based application demonstrates Cresco Labs’ deep regulatory expertise and thoughtful approach to meaningful local engagement. Organic licenses enable capital-efficient market entry, and our cash flow and balance sheet give us the financial flexibility to invest in and grow our scaled platform for the long term.”

This license advances Cresco Labs’ state-by-state growth strategy and ensures access to one of the largest patient populations in the United States. Texas is the nation’s second most populous state, approaching 30 million people, and continues to see ongoing legislative efforts to improve patient access and expand eligibility.

Cannabis News

Missouri Lawmakers Pass Bill To Ban Intoxicating Hemp THC Products, Sending It To Governor

Published

13 hours ago

April 4, 2026

admin

The legislation also includes provisions to protect the privacy of marijuana users and the right of cannabis workers to unionize.

By Rebecca Rivas, Missouri Independent

It would be a bill headed to the desk of Missouri Governor Mike Kehoe (R). remove all intoxicating hemp products from the shelves as of Nov. 12 — including THC seltzers currently sold in bars and grocery stores — in line with the state’s upcoming federal ban.

If Congress were to reverse course and decide to allow the sale of these products, Missouri would allow the sale of marijuana only in licensed dispensaries. And if Congress decides to delay the ban for a couple of years, Missouri would ban all products except liquor sales at dispensaries.

The House passed the bill sponsored by state Rep. Dave Hinman, R-O’Fallon, by a vote of 126 to 23. It passed the Senate Tuesday night and now goes to the governor for his signature or veto.

The bill also includes provisions to protect the privacy of marijuana users and the right of cannabis workers to organize, amendments that state senators added late Tuesday.

Hinman’s legislation was one of the first bills to pass the House this year. He previously told The Independent that the legislation was a priority for state leadership, including the governor, attorney general and House speaker.

Intoxicating hemp products containing as much as 1,000 mg of THC are being sold in smoke shops—outside of licensed marijuana dispensaries in Missouri—and are not regulated by any government agency. Missouri lawmakers have not passed legislation regulating these products since 2023.

The bill comes amid uncertainty about where the federal government will take regulation of these products.

President Donald Trump signed an executive order in December directing his administration to work with Congress to develop a framework that allows full-spectrum CBD products that contain some amount of THC.

On Wednesday, the Centers for Medicare and Medicaid Services unveiled an initiative that could $500 cover per year per 3mg hemp-derived THC and CBD product. for eligible users. Products under this program would be illegal in Missouri under the bill passed Thursday.

This story was first published by the Missouri Independent.

Marihuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Cannabis News

“There is more to Portugal’s medical cannabis story than recent turbulence”

Published

2 days ago

April 3, 2026

admin

Germany imported 2025 tons of medical cannabis. Part of that volume came from a Portuguese processor whose license had been revoked, which was unloaded below cost as it was reinstated. The episode sparked attention, and consequences followed. PTMC’s Joao Duarte believes that most of these conclusions are wrong. “Eight tons is not even 5% of what Germany consumes per year,” he says. “For that to result in price dumping, the math just doesn’t work.”

Structural price pressure
According to him, the price pressure in Portugal is mainly structural. “The more countries that get into production and start exporting, the lower the prices will be. Today, Colombia is exporting, Costa Rica is exporting, and Brazil, with the scale it can bring to outside cultivation, is not far behind. Canada has been the main volume supplier to markets in Germany, Australia, Israel and the UK due to the strength of low-priced flowers from European producers. Again, and fast.” It draws a direct line with what happened in the CBD market in previous years, when prices were compressed as supply expanded and operators without cost or quality advantages found themselves without a market. Medical flower THC, he says, is following the same logic over a longer timeline.

To lift the burden of this price pressure, the answer obviously lies in the right regulations and policies. These should be based on the principles of providing high quality medicines to patients. To achieve this, the flowers must reach the consumers shortly after they are picked. As simple as it sounds, proximity is Portugal’s real advantage. “The fresher the flower is when it reaches the patient, the better the quality,” he says. “Only proximity gives that.”

A turning point
As for the regulatory issue, Joao points to Portugal’s eight-year history of medical cannabis as a distinguishing feature, following last year’s police raids. Organizations that have long been involved in the licensing and enforcement framework have developed standards and experience in applying them. “Our GMP standards are real,” he says. “They are not a number on a certificate.”

The damage to the reputation of these raids, in his opinion, is exaggerated. “There is always a scandal in the industry,” he said. “That doesn’t necessarily mean it’s over, that a country’s economic sector has been kicked out. Canada, the largest exporter of cannabis, is the clearest example of that. Everyone remembers the CannTrust scandal in 2019, which made international headlines. That didn’t kill the Canadian industry until it became them, the regulatory system moved in their work. It looks like.”

EU-GMP clearance
One important area is EU GMP clearance, the practice of converting imported flowers through a European facility to obtain certification that the original material would not otherwise carry. “We would have more value growing the flowers than doing the conversion,” he says. For Portuguese producers, the practice reduces the premium that EU GMP certification must entail and makes it more difficult to distinguish domestically grown product from processed imports at the point of sale.

To each his own
Joao does not believe that other European countries can take Portugal’s place in the old continent’s cannabis industry. “This is simply because it’s not one thing for a country to be active in one sector and then push out another. It’s an open market, everyone participates at different levels.” As a neighbor, Joao cites Spain as an example. The country currently has less than ten licensed producers and has yet to build the export infrastructure or regulatory track required by the markets. “I don’t see Spain coming and taking over,” he says. “Both Spain and Portugal will take market share. Operators with established contracts will continue to move product. After that, it’s about quality and price.”

Denmark, he says, is an immediate competitive variable, producing significant quantities and moving into European markets with momentum. Portugal is currently among the top three to five exporters to Germany and has established positions in Australia, Israel and the United Kingdom. “This reflects accumulated capacity rather than regulatory time, and it’s not something that goes away because a processor loses its license,” he says.

A common European pricing policy, along the lines of the state-controlled model in France, is a mechanism that the industry should collectively push for. Without this, individual producers are left to absorb the cost pressures of suppliers operating on a scale that European policy has no current framework for. “We should aim to have good flowers,” he says. “We must not aim to demolish Portugal.”

For more information:
PTMC
ptmc.pt